StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2022 - 01 - 18
11
Sector
Commercial services
1
Finance
1
Health services
1
Health technology
6
Tags
Acquisition
9
Alliances
4
Als
18
America
6
Application
4
Biotechnology
5
Cancer
11
Cel
9
Ceo
4
Ces
50
China
5
Clinical-trials-phase-ii
8
Collaboration
5
Commercialization
5
Conference
15
Corporation
5
Covid
10
Covid-19
8
Deadline
4
Designation
8
Disease
5
Distribution
4
Drug
8
Earnings
8
Ema
8
Enroll
4
Fast track
4
Fast track designation
4
Fda
14
Financial results
13
Genetown
5
Group
7
Growth
8
Health
14
Intel
4
License
7
Market
4
N/a
234
Offering
4
Patent
4
People
6
Pharm-country
4
Pharma
6
Phase 2
8
Platform
6
Pons
4
Positive
4
Program
4
Report
25
Research
31
Response
4
Results
28
System
5
Technology
4
Test
11
Therapeutics
16
Therapy
4
Treatment
10
Trial
16
Work
6
Entities
Aptorum group limited
1
Celcuity inc.
1
Celularity inc - class a
1
Chimerix, inc.
1
Exact sciences corporation
1
Guardant health, inc.
1
Hookipa pharma inc.
1
Lantern pharma inc.
1
Qualigen therapeutics, inc.
1
Rafael holdings, inc.
1
Renovorx inc
1
Symbols
APM
1
CELC
1
CELU
1
CMRX
1
EXAS
1
GH
1
HOOK
1
LTRN
1
QLGN
1
RFL
1
RNXT
1
Exchanges
Nasdaq
10
Nyse
1
Crawled Date
2024 - 04 - 09
16
2024 - 04 - 08
15
2024 - 03 - 06
13
2024 - 03 - 05
23
2023 - 12 - 06
12
2023 - 11 - 28
11
2023 - 11 - 06
11
2023 - 11 - 03
19
2023 - 10 - 31
11
2023 - 10 - 23
19
2023 - 10 - 04
16
2023 - 10 - 03
13
2023 - 09 - 27
17
2023 - 09 - 11
12
2023 - 05 - 25
14
2023 - 04 - 19
12
2023 - 04 - 18
17
2023 - 04 - 17
17
2023 - 03 - 15
17
2023 - 03 - 14
25
2022 - 12 - 08
17
2022 - 12 - 01
11
2022 - 11 - 10
18
2022 - 10 - 12
11
2022 - 10 - 06
12
2022 - 10 - 05
18
2022 - 09 - 12
13
2022 - 06 - 06
11
2022 - 04 - 08
27
2022 - 03 - 09
13
2022 - 03 - 08
32
2022 - 03 - 07
12
2022 - 01 - 19
14
2022 - 01 - 18
11
2021 - 12 - 10
19
2021 - 12 - 09
13
2021 - 11 - 30
12
2021 - 11 - 12
16
2021 - 11 - 09
12
2021 - 10 - 28
11
2021 - 10 - 25
11
2021 - 10 - 13
10
2021 - 10 - 07
19
2021 - 10 - 04
10
2021 - 10 - 01
30
2021 - 09 - 30
11
2021 - 09 - 20
13
2021 - 09 - 14
10
2021 - 06 - 04
12
2021 - 06 - 03
11
2021 - 05 - 21
10
2021 - 05 - 20
13
2021 - 04 - 12
16
2021 - 04 - 10
15
2021 - 04 - 09
15
2021 - 04 - 08
10
2021 - 03 - 21
11
2021 - 03 - 10
16
2020 - 12 - 09
13
2020 - 12 - 01
20
Crawled Time
11:00
1
13:00
1
13:30
1
15:00
5
15:30
1
22:00
1
23:00
1
Source
renovorx.com
1
www.biospace.com
9
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
crawled date :
2022 - 01 - 18
save search
Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
Published:
2022-01-18
(Crawled : 23:00)
- prnewswire.com
EXAS
|
$63.99
0.2%
1.7M
|
Health Technology
|
-16.84%
|
O:
2.62%
H:
2.69%
C:
-3.39%
cologuard
ces
test
cancer
colorectal cancer
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
Published:
2022-01-18
(Crawled : 22:00)
- biospace.com/
CMRX
|
$0.91
-1.1%
350K
|
Health Technology
|
-84.67%
|
O:
-1.33%
H:
1.52%
C:
-5.07%
onc201
phase 2
research
positive
endocrine
cancer
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Published:
2022-01-18
(Crawled : 15:30)
- biospace.com/
GH
|
$16.62
2.85%
850K
|
Health Services
|
-79.17%
|
O:
-3.08%
H:
0.0%
C:
0.0%
health
blood
risk
lung cancer
test
cancer
enroll
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
LTRN
|
$6.12
2.0%
93K
|
Health Technology
|
-17.47%
|
O:
2.48%
H:
0.0%
C:
-11.41%
lp-100
solid tumors
ces
announces collaboration
drug
research
100
collaboration
cancer
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
CELU
|
$3.51
0.29%
27K
|
|
-15.46%
|
O:
4.83%
H:
0.0%
C:
-12.21%
cynk-101
fast track designation
treatment
fda
fast track
cel
positive
therapy
cancer
her2-
her2
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
QLGN
|
$0.291
-2.94%
38K
|
Health Technology
|
-71.45%
|
O:
-3.81%
H:
1.98%
C:
0.0%
therapeutics
cancer
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
RFL
4
|
$1.78
-1.11%
6.1K
|
Finance
|
-63.78%
|
O:
0.4%
H:
0.0%
C:
-8.42%
cpi-613
613
phase 2
als
ongoing
trial
gemcitabine
cancer
enroll
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
Published:
2022-01-18
(Crawled : 15:00)
- biospace.com/
HOOK
|
$0.7633
-5.75%
440K
|
Health Technology
|
-60.49%
|
O:
0.0%
H:
2.44%
C:
-1.46%
hb-200
fast track designation
treatment
fda
phase 2
fast track
trial
report
cancer
enroll
designation
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
Published:
2022-01-18
(Crawled : 13:30)
- biospace.com/
APM
|
$7.43
-2.88%
74K
|
Health Technology
|
475.19%
|
O:
-0.75%
H:
5.3%
C:
-3.79%
treatment
drug
patent
granted
cancer
repurposed
group
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
Published:
2022-01-18
(Crawled : 13:00)
- biospace.com/
CELC
|
$17.3
0.41%
18K
|
Commercial Services
|
49.18%
|
O:
-2.16%
H:
7.88%
C:
2.12%
fast track designation
fda
fast track
cel
fda fast track
cancer
breast cancer
designation
her2-
her2
metastatic breast cancer
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
Published:
2022-01-18
(Crawled : 11:00)
- renovorx.com
RNXT
|
$1.19
5.34%
4K
|
|
-72.17%
|
O:
-1.72%
H:
5.01%
C:
2.76%
treatment
conference
presentation
therapy
cancer
Gainers vs Losers
62%
38%
Top 10 Gainers
INVO
|
$2.78
265.79%
200M
|
Health Technology
EDBL
|
$7.4
62.64%
12M
|
SINT
|
$0.0366
59.83%
460M
|
Health Technology
RYDE
|
$3.89
42.49%
1.2M
|
n/a
GRTX
|
$0.237
39.41%
13M
|
Health Technology
VNDA
|
$5.28
30.37%
21M
|
Health Technology
VIRX
|
$0.912
27.59%
170K
|
Manufacturing
WISA
4
|
$7.72
26.56%
51M
|
Electronic Technology
LUXH
|
$1.045
26.06%
540K
|
RCAT
|
$1.41
25.89%
3.2M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.